Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Breast Neoplasms × Methylphenidate × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Fatigue 4 Prostatic Neoplasms 3 Sleep Wake Disorders 2 Neurotoxicity Syndromes 1 Hematologic Neoplasms 1 Depression 1 Cognitive Dysfunction 1 Central Nervous System Neoplasms 1 Breast Neoplasms 1

Interventions

Trastuzumab 254 Cyclophosphamide 214 Paclitaxel 212 Docetaxel 204 Capecitabine 158 Letrozole 138 Carboplatin 133 Doxorubicin 123 Fulvestrant 120 Bevacizumab 102 Anastrozole 88 Tamoxifen 85 Vinorelbine 79 Epirubicin 76 exemestane 75 Gemcitabine 72 Lapatinib 71 pertuzumab 69 Radiotherapy 62 Albumin-Bound Paclitaxel 61 pembrolizumab 60 palbociclib 51 eribulin 51 Cisplatin 48 130-nm albumin-bound paclitaxel 45 Everolimus 42 Neoadjuvant Therapy 37 Goserelin 37 Taxes 36 pyrotinib 33

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02970500 2023-03-23

CogMet

CHU de Quebec-Universite Laval

Phase 2 Terminated

Breast Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡